Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer

Clin Adv Hematol Oncol. 2007 Jun;5(6):456-8.
No abstract available

Publication types

  • Clinical Trial, Phase III

MeSH terms

  • Aged
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Breast Neoplasms / drug therapy*
  • Capecitabine
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / analogs & derivatives
  • Humans
  • Lapatinib
  • Middle Aged
  • Quinazolines / administration & dosage
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Receptor, ErbB-2 / drug effects
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Quinazolines
  • Lapatinib
  • Deoxycytidine
  • Capecitabine
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab
  • Fluorouracil